Haelim Kim

(A subsidiary of Kolon Corporation, a publicly traded global conglomerate)

• Oversee financial operations of a publicly traded pharmaceutical company, ensuring compliance with IFRS while referencing US GAAP standards as needed
• Oversee monthly, quarterly, and annual financial reporting, including P&L, balance sheets, and cash flow statements, for timely submission to headquarters and regulatory bodies.
• Lead the capitalization of $110M+ in R&D development costs for cell and gene therapy projects, ensuring adherence to industry-specific regulations.
• Collaborate with cross-functional teams to develop budgets, monitor variances, and provide strategic financial insights.
• Partnered with external auditors to ensure seamless Quarterly reviews, year-end audits and compliance with SOX and FSS regulations.
• Mentor and supervise a high-performing accounting team, driving operational efficiency and professional growth.

(An affiliate of Kolon Corporation, a publicly traded global conglomerate)

• Oversaw accounting operations for a $300M engineering plastics manufacturer, managing accounts payable/receivable, reconciliations, and monthly close processes.
• Prepared financial statements in compliance with K-IFRS and corporate policies, ensuring accurate reporting and regulatory compliance.
• Collaborated with internal teams to optimize budget controls, improve cost efficiency, and enhance financial transparency.
• Supported external audits and tax filings, streamlining documentation to meet corporate and regulatory requirements.
• Led process improvement initiatives, automating reporting systems to enhance operational efficiency.
• Received recognition from the CEO for significantly improving financial transparency and operational processes.